Memantina Stada (Memantine Hydrochloride)

Memantine hydrochloride blocks the NMDA‑type glutamate receptors in a non‑competitive manner. By reducing excessive calcium entry into neurons, it limits excitotoxic damage caused by over‑activation of glutamate pathways, thereby protecting brain cells and supporting neuronal function.

The dose of Memantina Stada is determined by the prescribing physician based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made according to professional guidelines and individual patient needs.

The safety of memantine hydrochloride in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Memantina Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Memantina Stada (memantine) belongs to the NMDA‑receptor antagonist class, whereas drugs like donepezil or rivastigmine are acetylcholinesterase inhibitors. Memantine targets glutamate‑mediated excitotoxicity, offering a different mechanism that can be used alone or in combination with cholinergic agents for broader symptom control.

Memantina Stada should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Memantina Stada is taken orally, usually as a tablet, with or without food. The exact administration schedule—once daily or divided doses—depends on the prescriber’s instructions and the patient’s tolerance and therapeutic response.

Serious risks include seizures, severe allergic reactions (e.g., rash, swelling, breathing difficulty), and cardiac arrhythmias. Patients should be monitored for these events, and any sudden or severe symptoms should prompt immediate medical evaluation.

Memantina Stada is contraindicated in patients with known hypersensitivity to memantine hydrochloride or any of the tablet’s excipients. Caution is also advised for individuals with severe renal impairment, uncontrolled epilepsy, or those taking other NMDA‑antagonist medications.